Skip to main content

Arcturus Therapeutics Holdings Inc. (ARCT)

NASDAQ: ARCT · IEX Real-Time Price · USD
44.50 0.69 (1.56%)
Oct 21, 2021 12:42 PM EDT - Market open
Market Cap1.16B
Revenue (ttm)8.70M
Net Income (ttm)-163.04M
Shares Out26.32M
EPS (ttm)-6.49
PE Ration/a
Forward PE1.70
Dividendn/a
Ex-Dividend Daten/a
Volume98,066
Open43.71
Previous Close43.81
Day's Range43.45 - 45.00
52-Week Range24.87 - 129.71
Beta2.81
AnalystsBuy
Price Target78.46 (+76.3%)
Est. Earnings DateNov 8, 2021

About ARCT

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issue...

IndustryBiotechnology
Founded2013
Employees118
Stock ExchangeNASDAQ
Ticker SymbolARCT
Full Company Profile

Financial Performance

In 2020, ARCT's revenue was $9.54 million, a decrease of -54.12% compared to the previous year's $20.79 million. Losses were -$72.15 million, 177.6% more than in 2019.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is 78.46, which is an increase of 76.33% from the latest price.

Price Target
$78.46
(76.33% upside)
Analyst Consensus: Buy

News

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16 hours ago - Business Wire

3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will Skyrocket

These growth stocks could rebound in a big way.

Other symbols:CRSPTDOC
2 days ago - The Motley Fool

Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?

The company disappointed last year, but things may be turning around.

Other symbols:MRNAPFE
6 days ago - The Motley Fool

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154,...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on th...

1 week ago - Business Wire

After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?

Three healthcare giants are vying for the prize.

Other symbols:BNTXMRNAPFESNY
2 weeks ago - The Motley Fool

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-1...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

4 weeks ago - Business Wire

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARC...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine

4 weeks ago - Business Wire

7 Busted Biotech Stocks Due for a Rebound

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...

Other symbols:AMRNARNABLUESAVATBPH
1 month ago - InvestorPlace

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

1 month ago - Business Wire

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

1 month ago - Business Wire

Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More

With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.

Other symbols:SDCSQSPVSCOBHVNOCUL
2 months ago - 24/7 Wall Street

Arcturus Therapeutics Stock Jumps On mRNA COVID-19 Vaccine Update

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported a Q2 EPS loss of $(2.07), beating the consensus of $(2.14). The cash balance totaled $433.6 million.

Other symbols:MRNA
2 months ago - Benzinga

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -4.02% and -27.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Prog...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

2 months ago - Business Wire

Earnings Previews: AMC, New Oriental Education and 3 Cathie Wood Picks

More than a third of earnings reports released Friday morning failed to meet consensus estimates for profits, revenues or both.

Other symbols:AMCEDUDDDVUZI
2 months ago - 24/7 Wall Street

Why Arcturus Therapeutics Stock Is Soaring Today

The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country.

2 months ago - The Motley Fool

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on th...

2 months ago - Business Wire

Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to Decline

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam

The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19 vaccine candidate targeting variants of con...

2 months ago - Benzinga

Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its investigational COVID-19 vaccines for sale and use within Viet...

2 months ago - Benzinga

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investi...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19

2 months ago - Business Wire

Can Last Year's Biggest Vaccine Stocks Crush the Market Again?

These players delivered triple- and quadruple-digit gains.

2 months ago - The Motley Fool

Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornit...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for OTC Deficiency

2 months ago - Business Wire

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

2 months ago - Business Wire

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO, Calif.--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

3 months ago - Business Wire